Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

OBJECTIVES: To evaluate the effect of subcutaneous (s.c.) secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic progression in patients with psoriatic arthritis (PsA). METHODS: Adults (n=996) with active PsA were randomised 2:2:2:3 to s.c. secukinumab 300 mg or 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip, van der Heijde, Désirée, Landewé, Robert, Mpofu, Shephard, Rahman, Proton, Tahir, Hasan, Singhal, Atul, Boettcher, Elke, Navarra, Sandra, Meiser, Karin, Readie, Aimee, Pricop, Luminita, Abrams, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965348/
https://www.ncbi.nlm.nih.gov/pubmed/29550766
http://dx.doi.org/10.1136/annrheumdis-2017-212687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965348/
https://www.ncbi.nlm.nih.gov/pubmed/29550766
http://dx.doi.org/10.1136/annrheumdis-2017-212687

Ejemplares similares